Streetbeat News

Regulatory

ABBV

AbbVie Inc (NYSE:ABBV) announced that its investigational drug Elahere met the primary endpoint in a Phase 2 trial for heavily pre-treated ovarian cancer patients. The study showed a 51.9% objective response rate and a median duration of response of 8.25 months. The safety profile was consistent with previous studies. Full data will be presented at a future medical meeting. Elahere, acquired through a $10 billion acquisition of Immunogen Inc, has also received FDA approval for certain ovarian cancer patients.

Portfolio Pulse from Vandana Singh

June 06, 2024 | 5:02 pm

BYFC

Broadway Financial Corporation (NASDAQ:BYFC) has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing its Form 10-Q for the period ended March 31, 2024. Nasdaq has closed the matter.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 5:02 pm

GNS

Genius Group shares are trading higher following the company's announcement of compliance with NYSE Guidelines on audit opinion and the issuance of 2024 guidance.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 4:36 pm

IDAI

Trust Stamp has received a non-compliance notice from Nasdaq for not meeting the minimum stockholders' equity requirement as of May 30.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 4:24 pm

EWJ

MS

MUFG

Japan's Securities & Exchange Surveillance Commission (SESC) is reportedly seeking action against MUFG Bank, Mitsubishi UFJ Morgan Stanley Securities, and Morgan Stanley MUFG Securities.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 4:23 pm

MUFG

Japan's Securities and Exchange Surveillance Commission is considering recommending punitive action against MUFG Bank and two securities companies under Mitsubishi UFJ Financial Group for allegedly sharing customer information without consent. The entities involved are MUFG Bank, Mitsubishi UFJ Morgan Stanley Securities, and Morgan Stanley MUFG Securities.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 4:20 pm

BMY

REPL

Replimune Group Inc (NASDAQ:REPL) reported positive topline results from its IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma, showing a 33.6% overall response rate. Bristol-Myers Squibb Co’s (NYSE:BMY) Nivolumab, sold as Opdivo, was used in the trial. REPL shares surged 28.40% following the news.

Portfolio Pulse from Vandana Singh

June 06, 2024 | 4:16 pm

JPM

USDTUSD

JPMorgan's recent report highlights the uncertain future of cryptocurrency regulation in the US, with potential opposition to CBDCs and non-compliant stablecoins. Key regulatory initiatives are stalled, creating a mixed outlook for the crypto industry.

Portfolio Pulse from Murtuza Merchant

June 06, 2024 | 4:15 pm

HOOD

Robinhood Inc. (NASDAQ:HOOD) has acquired Bitstamp, a major crypto exchange, to accelerate its vision of reorganizing the financial system through cryptocurrencies. The acquisition has been praised by industry experts as a bold and significant move, despite Robinhood recently receiving a wells notice from the SEC. The deal is expected to have long-term implications for the fintech sector and the broader crypto market.

Portfolio Pulse from Murtuza Merchant

June 06, 2024 | 4:11 pm

LLY

Eli Lilly's Alzheimer's drug, donanemab, will face an FDA advisory committee vote on June 10 to assess its benefit-risk profile based on Phase 3 study data. The study showed statistically significant results in reducing cognitive decline and improving daily function in Alzheimer's patients.

Portfolio Pulse from Vandana Singh

June 06, 2024 | 4:07 pm